Tandem Diabetes Care had its Relative Strength (RS) Rating upgraded from 66 to 81 Friday.
This proprietary rating identifies technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History reveals that the market's biggest winners often have an 80 or better RS Rating as they begin their biggest climbs.
Hone Your Stock-Picking Skills By Focusing On These Factors
Tandem Diabetes Care has risen more than 5% past a 31.07 entry in a first-stage cup with handle, meaning it's now out of a proper buy zone. Look for the stock to create a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week line.
Tandem Diabetes Care showed 0% EPS growth in its most recent report, while sales growth came in at 31%.
The company holds the No. 53 rank among its peers in the Medical-Products industry group. Globus Medical, Boston Scientific and Penumbra are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
